MAPT and Alzheimer disease: The biochemical markers Amyloid beta (Aβ) 1–42 and tau in the cerebrospinal fluid (CSF), that are decreased and elevated in AD, respectively, offer reasonable sensitivity and specificity for the diagnosis of AD, especially if analyzed together, however, their ability to differentiate AD from other forms of dementia, such as DLB, is limited [5], [6].